Live
FierceBiotechAmgen abandons candidates for cancer, Sjögren’s syndrome over weak ph. 2 dataBioPharma DiveTwo biotechs raise a combined $556M in latest spurt of IPOsThermo FisherHow Investors Are Reacting To Thermo Fisher Scientific (TMO) Expanding Its U.S. Bioprocess Design Center - Yahoo FinanceIlluminaIllumina Reports Financial Results for First Quarter of Fiscal Year 2026 - PR NewswireScienceDeepfakes are everywhere. The godfather of digital forensics is fighting backEndpoints NewsFDA's oncology advisors vote against 'new paradigm' in AstraZeneca trialEndpoints NewsKrazati fails confirmatory trial in colorectal cancer, putting approval at risk10x Genomics BlogWhy 10x Genomics Stock Is Surging Today - TipRanksFierceBiotechAstraZeneca's camizestrant ambitions stumble as FDA panel rejects novel oral SERD proposalEndpoints NewsHouse panel calls to ban China trial data from FDA drug trial applicationsEndpoints NewsCourt dismisses part of Lilly lawsuit against Empower, some claims can proceedEndpoints NewsSupreme Court questions how far generics makers can go with 'skinny label' drugs
BioPharma Dive Mar 16, 2026

CytomX surges on positive data for ‘masked’ ADC in colorectal cancer

CytomX surges on positive data for ‘masked’ ADC in colorectal cancer

Original
Body unavailable. Use the original source.